Fig. 6.
Cisplatin and TA-HPV treatment generates greater anti-tumor effect and E7-specific immune response than cisplatin and wild typeVV. Groups of C57BL/6 mice (five per group) were s.c. challenged with 1 × 105 per mouse of TC-1 tumor cells on day 0. Tumor-bearing mice were treated with cisplatin and either wild type vaccinia virus or TA-HPV according to the schedule outlined in Fig. 1a. a Line graph depicts tumor volume over time. b Peripheral blood samples (collected from the tail vein on day 10 after last treatment) were stained with PE-conjugated HPV16 H-2Db–RAHYNIVTF (E7) tetramer reagent and FITC-conjugated CD8+ cells. Left panel is representative flow cytometry analysis. Right panel is a bar graph representing the percentage of E7-specific CD8+ T cells/3 × 104 CD8+ T cells of peripheral blood. Columns, mean; bars, SE (*p < 0.01)